Fernando Cabanillas

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?
    Fernando Cabanillas
    University of Puerto Rico School of Medicine, San Juan, Puerto Rico
    P R Health Sci J 29:215-7. 2010
  2. doi request reprint Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support
    Fernando Cabanillas
    Auxilio Cancer Center, Auxilio Mutuo Hospital, San Juan, 00927 Puerto Rico
    Leuk Lymphoma 53:1929-33. 2012
  3. pmc Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors
    Fernando Cabanillas
    University of Puerto Rico School of Medicine, San Juan, Puerto Rico
    P R Health Sci J 31:52-8. 2012
  4. doi request reprint New developments in the field of diffuse large cell lymphoma
    Fernando Cabanillas
    Auxilio Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico 00927, USA
    Hematology 17:S98-100. 2012
  5. ncbi request reprint High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
    F Cabanillas
    Auxilio Mutuo Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico
    Ann Oncol 17:1424-7. 2006
  6. doi request reprint Front-line management of diffuse large B cell lymphoma
    Fernando Cabanillas
    Department of Medicine, University of Puerto Rico School of Medicine, Centro de Cancer, Auxilio Mutuo, San Juan, Puerto Rico
    Curr Opin Oncol 22:642-5. 2010
  7. doi request reprint Non-Hodgkin's lymphoma: the old and the new
    Fernando Cabanillas
    Auxilio Cancer Center, San Juan, PR, USA
    Clin Lymphoma Myeloma Leuk 11:S87-90. 2011
  8. ncbi request reprint Dose dense CHOP: when more is not always better!
    Fernando Cabanillas
    Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
    Leuk Lymphoma 48:845-6. 2007
  9. ncbi request reprint BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome
    George Z Rassidakis
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 8:488-93. 2002
  10. ncbi request reprint Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:120-7. 2006

Detail Information

Publications57

  1. ncbi request reprint Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?
    Fernando Cabanillas
    University of Puerto Rico School of Medicine, San Juan, Puerto Rico
    P R Health Sci J 29:215-7. 2010
    ..Nor do we know which histological types of cancers, if any, are susceptible to this agent. Finally, we don't know what the recommended dose of Vitamin C is, if there is indeed such a dose, that can produce an anti-tumor response...
  2. doi request reprint Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support
    Fernando Cabanillas
    Auxilio Cancer Center, Auxilio Mutuo Hospital, San Juan, 00927 Puerto Rico
    Leuk Lymphoma 53:1929-33. 2012
    ..The results with R-CHOP-GM-CSF every 14 days are encouraging, and merit a prospective comparative clinical trial against R-CHOP-14 in order to elucidate the contribution of GM-CSF...
  3. pmc Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors
    Fernando Cabanillas
    University of Puerto Rico School of Medicine, San Juan, Puerto Rico
    P R Health Sci J 31:52-8. 2012
    ..The present study aimed to determine pre-treatment prognostic factors that are associated with an unfavorable outcome...
  4. doi request reprint New developments in the field of diffuse large cell lymphoma
    Fernando Cabanillas
    Auxilio Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico 00927, USA
    Hematology 17:S98-100. 2012
    ..New entities such as breast implant associated anaplastic large cell lymphoma will be described...
  5. ncbi request reprint High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
    F Cabanillas
    Auxilio Mutuo Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico
    Ann Oncol 17:1424-7. 2006
    ..Rituximab is associated with low incidence of hypogammaglobulinemia and little morbidity. Our experience with the combination of rituximab + chemotherapy suggested the opposite...
  6. doi request reprint Front-line management of diffuse large B cell lymphoma
    Fernando Cabanillas
    Department of Medicine, University of Puerto Rico School of Medicine, Centro de Cancer, Auxilio Mutuo, San Juan, Puerto Rico
    Curr Opin Oncol 22:642-5. 2010
    ..The purpose of this review is to discuss the pertinent advances and to highlight areas of consensus and controversy...
  7. doi request reprint Non-Hodgkin's lymphoma: the old and the new
    Fernando Cabanillas
    Auxilio Cancer Center, San Juan, PR, USA
    Clin Lymphoma Myeloma Leuk 11:S87-90. 2011
    ..Their future role in front-line management remains to be determined...
  8. ncbi request reprint Dose dense CHOP: when more is not always better!
    Fernando Cabanillas
    Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
    Leuk Lymphoma 48:845-6. 2007
  9. ncbi request reprint BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome
    George Z Rassidakis
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 8:488-93. 2002
    ..Therefore, we correlated BAX expression with presenting features and clinical outcome in untreated patients with HD...
  10. ncbi request reprint Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:120-7. 2006
    ..In animal models, the encapsulation of vincristine into sphingomyelin liposomes or "sphingosomes" for injection (SV) has improved efficacy compared with conventional vincristine...
  11. ncbi request reprint A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma
    Chul S Ha
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 63:188-93. 2005
    ..MR was defined as disappearance of t(14;18) (q32;q21) amplified by polymerase chain reaction (PCR)...
  12. ncbi request reprint BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens
    George Z Rassidakis
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:3935-41. 2002
    ..We conclude that BCL-2 is frequently expressed by HRS cells in cHD and is associated with inferior FFS in patients treated with ABVD or equivalent regimens...
  13. ncbi request reprint Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study
    Chul S Ha
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:316-20. 2003
    ..This study was undertaken to update our experience with follicular lymphoma treated with central lymphatic irradiation (CLI)...
  14. ncbi request reprint Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21)
    Chul S Ha
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Cancer J 10:49-53. 2004
    ..This study was undertaken to study the molecular response rate of follicular lymphoma to C(H)OP-based therapy and to analyze prognostic factors for molecular response...
  15. ncbi request reprint Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 104:1624-30. 2004
    ..Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease...
  16. ncbi request reprint Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations
    Andre Goy
    Departments of Lymphoma, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Lab Invest 83:913-6. 2003
  17. ncbi request reprint Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
    Andre Goy
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
    J Clin Oncol 23:667-75. 2005
    ..Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma...
  18. ncbi request reprint The role of mitoxantrone in the treatment of indolent lymphomas
    Fredrick Hagemeister
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 10:150-9. 2005
    ..Because cure remains elusive in patients with indolent lymphoma, maximum prolongation of PFS with minimal toxicity and maximum preservation of quality of life should remain central goals of treatment...
  19. ncbi request reprint Stage III follicular lymphoma: long-term follow-up and patterns of failure
    Chul S Ha
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:748-54. 2003
    ..To analyze the long-term outcomes and pattern of failures for Stage III follicular lymphomas...
  20. ncbi request reprint Establishment and characterization of a new mantle cell lymphoma cell line M-1
    Andre Goy
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Leuk Lymphoma 45:1255-60. 2004
    ..The characterization of a new mantle cell lymphoma cell line is a unique tool for studying the biology of this subtype of lymphoma for which only a few cell lines have been established...
  21. ncbi request reprint Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 97:586-91. 2003
    ..The impact of endoscopic assessment on the management of MCL patients is unknown...
  22. ncbi request reprint Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:601-5. 2002
    ....
  23. ncbi request reprint European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:1731-8. 2002
    ....
  24. ncbi request reprint International prognostic index-based outcomes for diffuse large B-cell lymphomas
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:3083-8. 2002
    ..We present the results of doxorubicin-based chemotherapy with or without involved-field radiotherapy for patients with diffuse large B-cell lymphoma (DLBCL) according to the international prognostic index (IPI)...
  25. ncbi request reprint Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer
    David R Fogelman
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Anticancer Res 31:1417-20. 2011
    ..This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer...
  26. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
    ..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL...
  27. ncbi request reprint An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease
    Gregory M Chronowski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 95:2534-8. 2002
    ..The relative importance of prognostic factors in patients with early-stage Hodgkin disease remains controversial. The purpose of this study was to evaluate prognostic factors among patients who received chemotherapy before radiotherapy...
  28. ncbi request reprint Thalidomide for patients with recurrent lymphoma
    Barbara Pro
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1186-9. 2004
    ..However, its activity against other lymphoid tumors is unknown. The authors reported their experience with thalidomide in patients with recurrent/refractory non-Hodgkin lymphoma and in patients with Hodgkin disease...
  29. doi request reprint Epigenetic therapy of lymphoma using histone deacetylase inhibitors
    Maribel Cotto
    University of Puerto Rico, School of Medicine, Hematology Medical Oncology Section, San Juan, Puerto Rico
    Clin Transl Oncol 12:401-9. 2010
    ..Several ongoing trials are already exploring HDACi combinations in various types of cancers. Their role in front-line management remains to be determined...
  30. ncbi request reprint Metabolic abnormalities in lymphoma
    Fernando Cabanillas
    Centro de Cancer Auxilio Mutuo, San Juan, Puerto Rico
    Clin Lymphoma 3:S32-6. 2002
    ..If these syndromes are identified promptly, they can be corrected. Guidelines for identifying metabolic abnormalities in lymphoma patients, as well as management suggestions, are presented..
  31. ncbi request reprint Severe anemia of rapid onset in an inmunocompromised host
    Ezequiel Rivera Rodríguez
    Section of Hematology Oncology, Auxilio Mutuo Cancer Center, San Juan, PR
    Bol Asoc Med P R 100:42-6. 2008
    ..The reticulocyte count, bone marrow picture and PCR for DNA for Parvovirus B19 are essential for diagnosis...
  32. ncbi request reprint Evaluation of Breast Imaging Reporting and Data System Category 3 mammograms and the use of stereotactic vacuum-assisted breast biopsy in a nonacademic community practice
    Angela Mendez
    Auxilio Mutuo Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico
    Cancer 100:710-4. 2004
    ....
  33. ncbi request reprint Quantitative assessment of disease involvement by follicular lymphoma using real-time polymerase chain reaction measurement of t(14;18)-carrying cells
    Woo In Lee
    Department of Laboratory Medicine, Kyung Hee University College of Medicine, Seoul, Korea
    Int J Hematol 79:152-6. 2004
    ..The technique has the potential to be a useful tool in the diagnosis of FL, disease assessment, and prognosticating patients' clinical outcomes...
  34. ncbi request reprint Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma
    Barbara Pro
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Lymphoma 47:1818-21. 2006
    ..The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL...
  35. ncbi request reprint Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy
    Gregory M Chronowski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 55:36-43. 2003
    ..Cardiac toxicity and second malignancies, particularly the incidence of solid tumors in terms of the RT field size treated, were also examined...
  36. ncbi request reprint Radiotherapy alone for lymphocyte-predominant Hodgkin's disease
    Pamela J Schlembach
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Cancer J 8:377-83. 2002
    ..The purpose of the study was to analyze the results with radiotherapy alone in a select group of asymptomatic adults with nonbulky, early-stage lymphocyte-predominant Hodgkin's disease...
  37. pmc Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors
    George Z Rassidakis
    Am J Pathol 160:2309-10. 2002
  38. ncbi request reprint Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma
    Apostolia M Tsimberidou
    Department of Lymphoma and Myeloma, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:4351-7. 2002
    ..In conclusion, both regimens were associated with high rates of response and survival. ATT was associated with substantially longer FFS, but it was more toxic than FND...
  39. ncbi request reprint Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections
    George Z Rassidakis
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 118:328-34. 2002
    ..We conclude that the highest ARs in PTCLs are found in enteropathy-type T-cell lymphoma and ALK-positive ALCL, and that AR can be assessed reliably by using a tissue microarray...
  40. ncbi request reprint Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:2453-63. 2002
    ....
  41. ncbi request reprint CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome
    George Z Rassidakis
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1278-87. 2002
    ..Therefore, we correlated CD20 expression with presenting features and clinical outcome of untreated patients with classical HD...
  42. ncbi request reprint Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone
    Andreas H Sarris
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 29:48-55. 2002
    ..The presence of cells with t(14;18) and their numbers are prospectively quantitated in blood and marrow of patients treated with FND plus rituximab to determine their clinical significance both at presentation and during therapy...
  43. ncbi request reprint Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas
    Hoon K Lee
    Department of Radiation Oncology, Box 97, M D Anderson Cancer Center, 1515 Holcombe Blvd, University of Texas, Houston, TX 77030 4009, USA
    Leuk Lymphoma 43:1769-75. 2002
    ..Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses > or = 45 Gy, warrant investigation...
  44. ncbi request reprint Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma
    John F Seymour
    Department of Haematology, The Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    J Clin Oncol 21:2115-22. 2003
    ..We investigated the potential for combined-modality therapy to increase the disease-free survival for such patients...
  45. ncbi request reprint Second malignancies after chemotherapy and radiotherapy for Hodgkin disease
    Gregory M Chronowski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Am J Clin Oncol 27:73-80. 2004
    ..08). In an effort to reduce the risk of second malignancies, we have stopped using the alkylating agents nitrogen mustard and procarbazine and elective paraaortic and splenic radiotherapy after chemotherapy...
  46. ncbi request reprint Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy
    Carlo Visco
    Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, USA
    Leuk Lymphoma 45:2085-92. 2004
    ..0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT...
  47. ncbi request reprint Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:345-53. 2005
    ....
  48. ncbi request reprint Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis
    Carlo Visco
    Department of Hematology, Ospedale S Bortolo, Vicenza, Italy
    Eur J Haematol 77:387-94. 2006
    ..To evaluate the prognostic role of pretreatment serum levels of soluble CD30 (sCD30) in patients with advanced stage classical Hodgkin's lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine or equivalent regimens...
  49. ncbi request reprint Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy
    Bouthaina S Dabaja
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 98:1021-8. 2003
    ....
  50. ncbi request reprint Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  51. ncbi request reprint Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center
    Qi Liu
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1582-9. 2006
    ..Advanced-stage follicular lymphoma is considered incurable. The pace of improvements in treatment has been slow. This article analyzes five sequential cohorts of patients with stage IV follicular lymphoma treated between 1972 and 2002...
  52. ncbi request reprint Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome
    Marco Herling
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2114-20. 2003
    ..We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome...
  53. ncbi request reprint Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance
    Katharina Clodi
    St Anna Kinderspital, Vienna, Austria
    Cancer 94:1-5. 2002
    ..In this study, the authors investigated the hypothesis that the survival of H/RS cells was similarly promoted by an augmented CD40L signals in HD patients...
  54. ncbi request reprint Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma
    Bouthaina S Dabaja
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:321-4. 2003
    ..However, it can present in non-GI primary sites. This study was conducted to determine the incidence of gastric involvement in non-GI presentation of MALT lymphoma...
  55. ncbi request reprint Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma
    George Z Rassidakis
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2213-20. 2003
    ..Future studies should explore the underlying molecular mechanisms of MUC-1 expression in these tumors and its role as a target for novel therapeutic strategies...
  56. ncbi request reprint Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma
    Javier P Berrios-Rivera
    Division of Epidemiology, University of Texas School of Public Health, Houston, Texas 77030, USA
    Am J Clin Oncol 30:163-71. 2007
    ..The objective of this study was to determine the variations in the use of chemotherapy and radiation therapy in a large nationwide and population-based cohort of older patients with non-Hodgkin lymphoma (NHL)...
  57. ncbi request reprint Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma
    Apostolia Maria Tsimberidou
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, USA
    Leuk Lymphoma 43:1589-98. 2002
    ..We conclude that patients with follicular lymphoma are more frequently positive, have higher numbers of circulating cells with t(14;18), which exceed upper normal limit more frequently than in volunteer blood donors...